ESG risk score 26.49
Environmental score -
Social score -
Governance score -
ESG risk category Medium
Negligible Low Med High Severe
0-10 10-20 20-30 30-40 40+
BioNexus Gene Lab Corp..
000.00
0.00 / 0.00%
00:00:00
52 week range
0000.00 000.00
Symbol BGLC:xnas
Currency USD
NASDAQ (Small cap)
Open Closed
15 minutes delayed
Data provided by 
This information is not currently available for this instrument. Refresh the page or try again later.
Want to start investing?
Trade stocks with a broker trusted by over 1.5 million clients. Investing involves risk. You may lose some or all of your investment.
Chart
This information is not currently available for this instrument. Refresh the page or try again later.
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
This information is not currently available for this instrument. Refresh the page or try again later.
Returns
Year to date (YTD) -48.61%
1 year -23.97%
3 years -94.87%
Data provided by 
Key stats
Price/earnings (LTM) -
Dividend yield (LTM) -
EPS (LTM) -1.61
Volatility (30 days) 37.03%
Data provided by
Analyst consensus
Average rating -
Rating Analysts
Buy
-
Overweight
-
Hold
-
Underweight
-
Sell
-
Target price -
Implied return -
Last updated -
Data provided by
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Data provided by 
/ 
/ Financials
Q1 Q2 Q3 Q4
Income statement
Revenue XXXXXXX XXXXXXX XXXXXXX XXXXXXX
EBITDA XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Net income XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Balance sheet
Total assets XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Total debt XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Ratios
Price/sales XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Earnings per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Dividend per share XXXXXXX XXXXXXX XXXXXXX XXXXXXX
Return on equity XXXXXXX XXXXXXX XXXXXXX XXXXXXX
About BioNexus Gene Lab Corp..
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
Sector Industrials
Industry -
Market cap 0.004979659bn
Data provided by /
/ Frequently asked questions
To buy BioNexus Gene Lab Corp.. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for BioNexus Gene Lab Corp.. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for BioNexus Gene Lab Corp.. is BGLC:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
BioNexus Gene Lab Corp.. has its primary listing on NASDAQ (Small cap). You can trade BioNexus Gene Lab Corp.. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, BioNexus Gene Lab Corp.. is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include BioNexus Gene Lab Corp.. as part of a broader investment portfolio.